Bettach Emmanuel, Wiener Rony, Brosh Koby, Zadok David, Goldberg Mordechai
Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel.
Eur J Ophthalmol. 2024 Jul;34(4):NP20-NP24. doi: 10.1177/11206721241247588. Epub 2024 Apr 15.
This case report aims to report the development of cystoid macular edema (CME) unilaterally following the administration of bimatoprost implant (Durysta) injections in both eyes for the treatment of primary open-angle glaucoma (POAG).
An 84-year-old female patient, previously diagnosed with POAG, underwent bimatoprost implant (Durysta) injections in both eyes, spaced one month apart. Subsequently, the patient experienced a gradual decline in visual acuity in her left eye attributed to the development of CME. The condition resolved following a treatment regimen involving topical dexamethasone and nepafenac.
The use of bimatoprost implant may lead to the occurrence of CME. Ophthalmologists must vigilantly monitor patients post-implantation, especially if they exhibit visual symptoms or have risk factors for a CME.
本病例报告旨在报告双眼注射比马前列素植入剂（杜瑞斯塔）治疗原发性开角型青光眼（POAG）后单侧发生黄斑囊样水肿（CME）的情况。
一名84岁女性患者，既往诊断为POAG，双眼注射比马前列素植入剂（杜瑞斯塔），间隔1个月。随后，患者左眼视力逐渐下降，原因是发生了CME。经局部使用地塞米松和奈帕芬酸的治疗方案后病情得到缓解。
使用比马前列素植入剂可能导致CME的发生。眼科医生在植入后必须密切监测患者，尤其是那些出现视觉症状或有CME危险因素的患者。
